Clinical performance of paediatric zirconia crowns cemented with two luting agents: A 36-month split-mouth randomised controlled trial.

J DentMay 20, 2026 (epub)
Clinical ResearchPediatrics

Thikrayat Bani-Hani, Mays M Saleh, Abedelmalek K Tabnjh

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the clinical performance of Glass Ionomer Cement (GIC) versus self-adhesive resin cement for cementing zirconia crowns in children aged 3-5 years. Among 38 patients with 64 pair-matched incisors, GIC showed a cumulative retention rate of 95.3% at 36 months, while resin cement achieved 100% retention, with no significant difference between the two (p > 0.05).

Key findings

  • Cumulative retention rates for GIC were 96.9%, 95.3%, and 95.3% at 12, 24, and 36 months, respectively.
  • The resin cement group had a 100% retention rate with no debonding events recorded.
  • No significant differences in gingival index scores were found between the two cement types at any follow-up point.

Why it matters

Understanding the performance of different luting agents for zirconia crowns in pediatric dentistry is crucial for optimizing treatment outcomes and ensuring patient satisfaction. This study highlights viable options for clinicians when selecting cement materials.

Source

Published in J Dent. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.